Advertisement
Loading...

BioNexus Gene Lab Corp.

BGLC•NASDAQ
Healthcare
Medical - Diagnostics & Research
$2.02
$0.04(2.02%)
U.S. Market opens in 37h 54m

BioNexus Gene Lab Corp. (BGLC) Stock Overview

Explore BioNexus Gene Lab Corp.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap3.7M
P/E Ratio-1.26
EPS (TTM)$-1.61
ROE-0.39%
Fundamental Analysis

AI Price Forecasts

1 Month$4.88
3 Months$4.13
1 Year Target$7.37

BGLC Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioNexus Gene Lab Corp. (BGLC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 39.96, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $7.37.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.26 and a market capitalization of 3.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.98%
5-Day Change
-6.09%
1-Month Change
-7.38%
3-Month Change
-5.65%
6-Month Change
-55.43%
Year-to-Date (YTD) Change
-48.88%
1-Year Change
-33.58%
3-Year Change
-94.63%
5-Year Change
-98.60%
All-Time (Max) Change
-99.24%

Contact Information

https://www.bionexusgenelab.com
60 1 2212 6512
Tower B, Vertical Business Suite, Kuala Lumpur, NaN, 59200

Company Facts

30 Employees
IPO DateJan 8, 2021
CountryMY
Actively Trading

Frequently Asked Questions